CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 84 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,934,916 | -8.7% | 1,275,552 | -44.7% | 4.24% | -0.9% |
| Q2 2023 | $41,546,155 | +112105.0% | 2,305,558 | 0.0% | 4.28% | -7.5% |
| Q1 2023 | $37,027 | -12.2% | 2,305,558 | 0.0% | 4.63% | -1.8% |
| Q4 2022 | $42,192 | -99.9% | 2,305,558 | 0.0% | 4.72% | -12.8% |
| Q3 2022 | $45,281,000 | +5.3% | 2,305,558 | 0.0% | 5.40% | +7.2% |
| Q2 2022 | $42,999,000 | -3.5% | 2,305,558 | +13.6% | 5.04% | +16.5% |
| Q1 2022 | $44,552,000 | -22.7% | 2,029,701 | 0.0% | 4.33% | -5.4% |
| Q4 2021 | $57,664,000 | +63.1% | 2,029,701 | +20.8% | 4.57% | +108.5% |
| Q3 2021 | $35,358,000 | +11.7% | 1,679,701 | 0.0% | 2.19% | +5.7% |
| Q2 2021 | $31,662,000 | +93.4% | 1,679,701 | +56.8% | 2.08% | +123.8% |
| Q1 2021 | $16,371,000 | +8.3% | 1,071,428 | 0.0% | 0.93% | -2.3% |
| Q4 2020 | $15,118,000 | -10.0% | 1,071,428 | 0.0% | 0.95% | -39.4% |
| Q3 2020 | $16,789,000 | -10.6% | 1,071,428 | 0.0% | 1.56% | -20.4% |
| Q2 2020 | $18,771,000 | – | 1,071,428 | – | 1.97% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 2,030,616 | $31,028,000 | 6.04% |
| 5AM Venture Management, LLC | 1,362,286 | $20,816,000 | 3.75% |
| Burrage Capital Management LLC | 272,393 | $4,162,000 | 3.37% |
| Altium Capital Management LP | 361,930 | $5,530,000 | 1.54% |
| Vivo Capital, LLC | 2,214,138 | $33,832,000 | 1.19% |
| Bain Capital Life Sciences Investors, LLC | 1,071,428 | $16,371,000 | 0.93% |
| Perceptive Advisors | 3,659,381 | $51,606,000 | 0.65% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $2,154,000 | 0.50% |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 2,003,688 | $30,616,000 | 0.45% |
| Opaleye Management Inc. | 188,000 | $2,873,000 | 0.42% |